minimally symptomatic, metastatic hormone-refractory Prostate cancer
minimally symptomatic, metastatic hormone-refractory Prostate cancer is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.
- Classified under
- Indicated drugs
What you can answer from here — as of October 23, 2026
1Indicated drugWith each drug's targets and mechanismListed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not proseSign in
Which approved drugs for minimally symptomatic, metastatic hormone-refractory Prostate cancer share a target, and which companies have late-stage candidates against it?
Create a free account or log in to explore the full data card.
Create Account